Abstract: A computer-implemented method for scanning data including accessing a reference table including a grid of data cells arranged in columns and rows and containing reference data elements. Each of the rows may relate to one of a plurality of data subjects. The method may also include generating a list of reference subcombinations. The list of reference subcombinations may be generated by designating a primary column for uniquely identifying the data subjects and generating a plurality of first preliminary reference subcombinations. Each of the first preliminary reference subcombinations may include reference data elements gathered from the primary column and a second column of a single row of the reference table. The method may also include accessing a subject file having a plurality of data entries. Each of the data entries may include a plurality of logically-related and delimited subject data elements.

Abstract: In one implementation, a computer-implemented method includes receiving, at a computer system, a request to solicit one or more users to generate media content for a campaign; identifying, by the computer system, a plurality of content creating users; obtaining demographic data for a plurality of content consuming users who have accessed the media content that was generated by the plurality of content creating users; determining distributions of the plurality of content consuming users across a plurality of demographic categories; selecting, by the computer system, a portion of the plurality of content creating users based on a comparison of i) the one or more parameters for the campaign and ii) the distributions of the plurality of content consuming users across the plurality of demographic categories; and providing information that identifies an opportunity to generate media content for the campaign.

Abstract: In one implementation, a computer-implemented method includes receiving, at a computer system, a request to solicit one or more users to generate media content for a campaign; identifying, by the computer system, a plurality of content creating users; obtaining demographic data for a plurality of content consuming users who have accessed the media content that was generated by the plurality of content creating users; determining distributions of the plurality of content consuming users across a plurality of demographic categories; selecting, by the computer system, a portion of the plurality of content creating users based on a comparison of i) the one or more parameters for the campaign and ii) the distributions of the plurality of content consuming users across the plurality of demographic categories; and providing information that identifies an opportunity to generate media content for the campaign.

Abstract: The invention is directed to a method of inhibiting FLT3 tyrosine kinase activity or expression or reducing FLT3 kinase activity or expression in a cell or a subject comprising the administration of a farnesyl transferase inhibitor and a FLT3 kinase inhibitor selected from compounds of Formula I?: Included within the present invention is both prophylactic and therapeutic methods for treating a subject at risk of (or susceptible to) developing a cell proliferative disorder or a disorder related to FLT3.

Abstract: The invention is directed to alkylquinoline and alkylquinazoline compounds of Formula I: wherein R1, R2, R3, B, Z, G, Q and X are as defined herein, the use of such compounds as protein tyrosine kinase modulators, particularly inhibitors of FLT3 and/or c-kit and/or TrkB, the use of such compounds to reduce or inhibit kinase activity of FLT3 and/or c-kit and/or TrkB in a cell or a subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to FLT3 and/or c-kit and/or TrkB. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions such as cancers and other cell proliferative disorders.

Abstract: A method of reducing or inhibiting kinase activity of FLT3 in a cell or a subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to FLT3 using a compound of the present invention: or a solvate, hydrate, tautomer or pharmaceutically acceptable salt thereof. The present invention is further directed to methods for treating conditions such as cancers and other cell proliferative disorders.

Abstract: The invention is directed to compounds of the formula (I) described herein, a pharmaceutically acceptable salt thereof, or a prodrug thereof, and pharmaceutical compositions and methods of treatment.

Abstract: The invention is directed to a method of inhibiting FLT3 tyrosine kinase activity or expression or reducing FLT3 kinase activity or expression in a cell or a subject comprising the administration of a farnesyl transferase inhibitor and a FLT3 kinase inhibitor selected from compounds of Formula I?: Included within the present invention is both prophylactic and therapeutic methods for treating a subject at risk of (or susceptible to) developing a cell proliferative disorder or a disorder related to FLT3.

Abstract: The invention is directed to thienopyrimidines and thienopyridines compounds of Formula I and Formula II: where R1, R3, B, Z, Q, p, q and X are as defined herein, the use of such compounds as protein tyrosine kinase modulators, particularly inhibitors of FLT3, the use of such compounds to reduce or inhibit kinase activity of FLT3 in a cell or a subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to FLT3. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions such as cancers and other cell proliferative disorders.

Abstract: The invention is directed to thienopyrimidines and thienopyridines compounds of Formula I and Formula II: where R1, R3, B, Z, Q, p, q and X are as defined herein, the use of such compounds as protein tyrosine kinase modulators, particularly inhibitors of FLT3, the use of such compounds to reduce or inhibit kinase activity of FLT3 in a cell or a subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to FLT3. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions such as cancers and other cell proliferative disorders.

Abstract: The invention is directed to compounds of the formula (I) described herein, a pharmaceutically acceptable salt thereof, or a prodrug thereof, and pharmaceutical compositions and methods of treatment.

Abstract: To dynamically update an operating system, a new factory object may have one or more new and/or updated object instances. A corresponding old factory object is then located and its version is checked for compatibility. A dynamic update procedure is then executed, which includes (a) changing a factory reference pointer within the operating system from the old factory object to the new factory object. For the case of updated object instances, (b) hot swapping each old object instance for its corresponding updated object instance, and (c) removing the old factory object. This may be performed for multiple updated object instances in the new factory object, preferably each separately. For the case of new object instances, they are created by the new factory and pointers established to invoke them. A single factory object may include multiple updated objects from a class, and/or new object instances from different classes, and the update may be performed without the need to reboot the operating system.